Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Genor Biopharma Holdings's Revenue for the
six
months ended in Jun. 2025 was €3.89 Mil. Genor Biopharma Holdings's average Accounts Receivable for the
six
months ended in Jun. 2025 was €0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Genor Biopharma Holdings Receivables Turnover Related Terms
Genor Biopharma Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Genor Biopharma Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:67N0 vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Genor Biopharma Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genor Biopharma Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Genor Biopharma Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genor Biopharma Holdings (FRA:67N0) has a Receivables Turnover of 0.00 as of Jun. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genor Biopharma Holdings and its competitors.
Is Genor Biopharma Holdings' Receivables Turnover too high?
Genor Biopharma Holdings' current Receivables Turnover is 0.00. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' Receivables Turnover compare to VRTX and REGN?
Genor Biopharma Holdings' Receivables Turnover of 0.00 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.26, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genor Biopharma Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genor Biopharma Holdings's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current Receivables Turnover is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score
Get the complete analysis for FRA:67N0
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:67N0 has been successfully added to your 
